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Background
Equipoise implies that given a random unbiased sample
of trials, no significant difference would be expected in
the proportion favouring the new treatment to the pro-
portion favouring the standard treatment [1-3]. Previous
research reviewed treatment success and whether the
collective uncertainty principle is met in RCTs in the
US National Cancer Institute portfolio [4-6]. This paper
classifies clinical trials funded by the UK HTA pro-
gramme by results using the method applied to the US
Cancer Institute trials, and compares the two portfolios
[7].
Methods
Data on all completed randomised controlled trials
funded by the HTA programme 1993-2008 were
extracted. Each trial’s primary results was classified into
six categories; 1) statistically significant in favour of the
new treatment, 2) statistically significant in favour of the
control treatment 3) true negative, 4) truly inconclusive,
5) inconclusive in favour of new treatment or 6) incon-
clusive in favour of control treatment. Trials were classi-
fied by comparing the 95% confidence interval for the
difference in primary outcome to the difference specified
in the sample size calculation. The results were com-
pared with Djulbegovic’s analysis of NCI trials.
Results
Data from 51 superiority trials were included, involving
over 48,000 participants and a range of diseases and
interventions. 85 primary comparisons were available
because some trials had more than two randomised
arms or had several primary outcomes. The new treat-
ment had superior results (whether significant or not) in
61% of the comparisons (52/85 95% CI 49.9% to 71.6%).
The results were conclusive in 46% of the comparisons
(19% statistically significant in favour of the new treat-
ment, 5% statistically significant in favour of the control
and 22% true negative). The results were classified as
truly inconclusive (i.e. failed to answer the question
asked) for 24% of comparisons (20/85). HTA trials
included fewer truly inconclusive and statistically signifi-
cant results and more results rated as true negative than
NCI trials.
Conclusions
The pattern of results in HTA trials is similar to that of
the National Cancer Institute portfolio. Differences that
existed were plausible given the differences in the types
of trials -HTA trials are more pragmatic. The results
indicate HTA trials are compatible with equipoise. This
classification usefully summarises the results from clini-
cal trials and enables comparisons of different portfolios
of trials.
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